Germaine Cota, Chief Accounting Officer and Vice President of Finance at Astera Labs, Inc. (NASDAQ:ALAB), disposed of 35 shares of the company's common stock on November 16, 2026, generating proceeds of $7,230. The shares were sold at prices ranging from $201.895 to $209.6586 per share.
The transaction was not a discretionary trade by Cota. Instead, it was executed to fulfill tax withholding requirements associated with the vesting and settlement of previously granted restricted stock units. Astera Labs has elected a mandatory 'sell to cover' policy for such tax obligations, meaning the sale was automatic and required by the company's procedures.
Following the sale, Cota directly holds 26,505 shares of Astera Labs common stock. This figure includes 100 shares that were acquired on November 13, 2026, through the Astera Labs, Inc. 2024 Employee Stock Purchase Plan.
Astera Labs' stock is currently trading at $216.75. Over the past year, the shares have appreciated 52.63%, but they have declined 11.26% over the last six months. According to InvestingPro analysis, the company appears slightly overvalued at current levels, though 19 analysts have recently revised their earnings estimates upward. The platform provides comprehensive analysis with additional ProTips and detailed financial metrics for investors seeking deeper insights.
In other recent developments, Astera Labs reported stronger-than-expected third-quarter 2026 results. The company posted adjusted earnings of $1.32 per share on revenue of $584.9 million, surpassing Wall Street forecasts of $1.19 per share and $550.8 million, respectively. Revenue grew 49% from the previous quarter and 154% from the same period last year.
The company also noted that its Scorpio AI fabric line exceeded a $1 billion annualized revenue run rate, underscoring growing demand for its AI infrastructure products. Following these results, Northland upgraded Astera Labs' stock rating to Outperform, citing the strong quarter and raised guidance. Needham maintained a Buy rating but reduced its price target to $300, pointing to valuation compression in the AI sector despite improved estimates for the company. UBS also lowered its price target to $290 while keeping a Neutral rating, citing similar valuation concerns but raising revenue and earnings estimates for future years.
These recent developments reflect a dynamic period for Astera Labs as it navigates the evolving market landscape.